Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacogenomics J ; 8(2): 129-38, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17375033

ABSTRACT

The-216G/T, -191C/A, intron 1 and Arg497Lys epidermal growth factor receptor (EGFR) polymorphisms were evaluated in 92 advanced non-small-cell lung cancer patients treated with gefitinib, an EGFR tyrosine-kinase inhibitor. Improved progression free survival (PFS) was found in patients homozygous for the shorter lengths of intron 1 polymorphism (S/S; S=16 or fewer CA repeats; log-rank test (LRT) P=0.03) and for patients carrying any T allele of the -216G/T polymorphism (LRT, P=0.005). When considered together, patients with intron 1 S/S genotype and at least one T allele of -216G/T had improved PFS (LRT P=0.0006; adjusted hazard ratio (AHR), 0.60 (95% confidence interval, 0.36-0.98)) and overall survival (LRT P=0.02; AHR, 0.60 (0.36-1.00)) when compared with all others. The T allele of -216G/T was also associated with significantly higher rates of stable disease/partial response (P=0.01) and a significantly higher risk of treatment-related rash/diarrhea (P=0.004, multivariate model). EGFR intron 1 and -216G/T polymorphisms influence clinical outcomes in gefitinib-treated non-small-cell lung cancer patients.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , ErbB Receptors/genetics , Gene Expression Regulation, Neoplastic , Lung Neoplasms/drug therapy , Polymorphism, Genetic , Protein Kinase Inhibitors/therapeutic use , Quinazolines/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/mortality , Case-Control Studies , Diarrhea/chemically induced , Diarrhea/genetics , Disease-Free Survival , ErbB Receptors/antagonists & inhibitors , Exanthema/chemically induced , Exanthema/genetics , Female , Gefitinib , Homozygote , Humans , Introns , Kaplan-Meier Estimate , Lung Neoplasms/genetics , Lung Neoplasms/mortality , Male , Middle Aged , Odds Ratio , Promoter Regions, Genetic , Protein Kinase Inhibitors/adverse effects , Quinazolines/adverse effects , Risk Assessment , Risk Factors , Treatment Outcome
2.
Ann Neurol ; 41(6): 809-13, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9189043

ABSTRACT

The prevalence of known mutations in presenilin genes (PS1 and PS2) causing early-onset familial Alzheimer's disease (FAD) was assessed in a population of 98 singleton early-onset AD cases, 29 early-onset FAD cases, and 15 late-onset FAD cases. None of the cases tested positive for the eight mutations initially reported, and none of these mutations were observed in 60 age-matched controls. A novel mutation (R269H) in PS1 was found in a single case of early-onset AD but not in any other AD or control case. Thus, the PS mutations tested are quite rare in early-onset AD. Amyloid beta protein (A beta) deposition was investigated in the temporal cortex of the R269H mutation case using end-specific monoclonal antibodies to detect the presence of A beta x-40 and A beta x-42 subspecies. Stereologically unbiased tangle and neuropil thread counts were obtained from the same region. R269H PS1 mutation was associated with early age of dementia onset, higher amounts of total A beta and A beta x-42, and increased neuronal cytoskeletal changes. Thus, if the changes observed on this case prove to be typical of PS1 mutations, PS1 mutations may impact both amyloid deposition and neurofibrillary pathology.


Subject(s)
Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Membrane Proteins/genetics , Mutation , Neurofibrils/pathology , Age of Onset , Aged , Alzheimer Disease/pathology , Brain/metabolism , Brain/pathology , Female , Humans , Male , Middle Aged , Presenilin-1
4.
Nat Genet ; 5(1): 95-100, 1993 Sep.
Article in English | MEDLINE | ID: mdl-8220435

ABSTRACT

Familial Alzheimer's disease (FAD) is a genetically heterogeneous disorder that includes a rare early-onset form linked to mutations in the amyloid b protein precursor (APP) gene. Clues to the function of APP derive from the recent finding that it is a member of a highly conserved protein family that includes the mammalian amyloid precursor-like protein (APLP1) gene which maps to the same general region of human chromosome 19 linked to late-onset FAD. Here we report the isolation of the human APLP2 gene. We show that APLP2 is a close relative of APP and exhibits a very similar pattern of expression in the brain and throughout the body. Like APP, APLP2 contains a cytoplasmic domain predicted to couple with the GTP-binding protein G(o) indicating that it may be an additional cell surface activator of this G protein.


Subject(s)
Alzheimer Disease/genetics , Amyloid beta-Protein Precursor/genetics , Genes , Nerve Tissue Proteins/genetics , Amino Acid Sequence , Brain Chemistry , GTP-Binding Proteins/metabolism , Gene Expression Regulation , Humans , Molecular Sequence Data , Nerve Tissue Proteins/metabolism , Organ Specificity , Sequence Alignment , Sequence Homology, Amino Acid
5.
Genetica ; 91(1-3): 255-63, 1993.
Article in English | MEDLINE | ID: mdl-8125274

ABSTRACT

Inherited Alzheimer's disease is a genetically heterogeneous disorder that involves gene defects on at least five chromosomal loci. Three of these loci have been found by genetic linkage studies to reside on chromosomes 21, 19, and 14. On chromosomes 21, the gene encoding the precursor protein of Alzheimer-associated amyloid (APP) has been shown to contain several mutations in exons 16 and 17 which account for roughly 2-3% of familial Alzheimer's disease (FAD). The other loci include what appears to be a susceptibility gene on chromosome 19 associated with late-onset (> 65 years) FAD, and a major early-onset FAD gene defect on the long arm of chromosome 14. In other early- and late-onset FAD kindreds, the gene defects involved do not appear to be linked to any of these three loci, indicating the existence of additional and as of yet unlocalized FAD genes. This review provides a historical perspective of the search for FAD gene defects and summarizes the progress made in world-wide attempts to isolate and characterize the genes responsible for this disorder.


Subject(s)
Alzheimer Disease/genetics , Amyloid beta-Protein Precursor/genetics , Genes , Mutation/genetics , Alzheimer Disease/etiology , Chromosomes, Human , Genetic Linkage , Humans , Models, Biological
6.
J Biol Chem ; 268(1): 206-11, 1993 Jan 05.
Article in English | MEDLINE | ID: mdl-8380155

ABSTRACT

Methylprednisolone stimulates rabbit ileal neutral NaCl absorption; and aminoglutethimide, which decreases glucocorticoid levels, decreases NaCl absorption. Studies were carried out to determine the mechanism of these effects and to determine which members of the gene family of mammalian Na+/H+ exchangers were involved. Rabbits were treated subcutaneously with methylprednisolone (40 mg daily for 24 or 72 h), aminoglutethimide (100 mg twice daily for 72 h), or saline as a control. Ileal brush border membranes were prepared by magnesium precipitation, and brush border Na+/H+ exchange was determined by 22Na+ uptake over 3-8 s. The 22Na+ uptake experiments were performed in the presence of a voltage clamp using either valinomycin/potassium or tetramethylammonium/nitrate to eliminate potential contributions by other electrogenic transport processes. Methylprednisolone treatment approximately doubled ileal brush border Na+/H+ exchange, whereas aminoglutethimide led to a 50% decrease in Na+/H+ exchange. These effects were specifically on Na+ uptake with an acid inside pH gradient, whereas diffusive Na+ uptake (no pH gradient), glucose-dependent Na+ uptake, and glucose and Na+ equilibrium volumes were not affected. To determine if the increase in Na+/H+ exchange was associated with an increase in message expression, mRNA levels were measured by ribonuclease protection assay. Methylprednisolone stimulated the NHE-3 mRNA level by 4-6-fold at 24 h, which remained increased at 72 h. In contrast, messages for NHE-1 and NHE-2 were not affected by methylprednisolone. In summary, 1) methylprednisolone stimulation of rabbit ileal Na+ absorption is due to stimulation of ileal villus cell brush border Na+/H+ exchange; 2) basal ileal brush border Na+/H+ exchange is dependent on glucocorticoid levels; and 3) an increase in NHE-3 message, but not in NHE-1 or NHE-2 message, correlates with the stimulation of ileal brush border Na+/H+ exchange. It is likely that NHE-3 is an Na+/H+ exchanger that is involved in ileal Na+ absorption.


Subject(s)
Carrier Proteins/biosynthesis , Glucose/metabolism , Ileum/metabolism , Intestinal Absorption/drug effects , Intestinal Mucosa/metabolism , Methylprednisolone/pharmacology , Microvilli/metabolism , RNA, Messenger/metabolism , Sodium/metabolism , Aminoglutethimide/pharmacology , Animals , Carrier Proteins/genetics , Epithelium/metabolism , Kinetics , Male , Microvilli/drug effects , RNA, Messenger/genetics , Rabbits , Reference Values , Sodium-Hydrogen Exchangers , Sodium-Potassium-Exchanging ATPase/metabolism , Sucrase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...